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Introduction
Metastatic melanoma is highly therapy-resistant and standard chemotherapy has failed in clinical trials. Targeted therapy with new drugs, such as the BRAF-inhibitor PLX4720/4032/vemurafenib (1, 2), holds great promise but suffers from onset of resistance after ~7 months (3) (4) (5) (6) (7) . Defective apoptosis pathways are thought to be one barrier to effective systemic treatment of melanoma. For example, the frequent inactivation of ARF subverts p53 activity (8) and certain antiapoptotic BCL-2 family proteins are upregulated (9, 10) . Although BCL-2 in particular has attracted much attention, treatment targeting it (e.g. oblimersen, Genta, NJ) had only modest impact on survival in clinical trials (11, 12) . BCL-2 is only one of several related apoptosis proteins with altered expression in melanoma, for example, BCL-XL and MCL-1 are elevated during melanoma progression (9, 10) and these might prove superior targets for melanoma therapy.
ABT-737 (Abbott Laboratories, Abbott Park, IL) is a BH3-mimetic with a similar binding profile to the proapoptotic BH3-only protein BAD; it strongly inhibits the activity of BCL-2, BCL-XL and BCL-w but not MCL-1 or BFL-1/A1, for which it has negligible affinity (13, 14) . ABT-737 is effective as a single agent in preclinical models of lymphomas and small-cell lung carcinomas (SCLC) -cancers with low MCL-1 expression (13, (15) (16) (17) . It also sensitizes tumors to the effects of chemotherapy and radiotherapy (13, 15, 16, 18, 19) .
Apoptosis is initiated by the release of apoptogenic mediators, such as cytochrome C, from the mitochondrion, controlled by proapoptotic proteins BAK and BAX (20) Author Manuscript Published OnlineFirst on December 15, 2011; DOI: 10.1158/1078-0432.CCR- specifically regulate BAK (21) . In the presence of ABT-737, BCL-XL is inhibited, so BAK activity is determined by MCL-1 and BFL-1. There is clear evidence that MCL-1 is a major factor in sensitivity to ABT-737 (e.g. 14) but the role of BFL-1 is less clear.
Evidence currently suggests BFL-1 functions in a similar manner to MCL-1 (22) and its expression is correlated with sensitivity to ABT-737 (23, 24) .
Prior studies suggest that drugs that repress MCL-1 or induce NOXA sensitize cells to ABT-737 in a variety of tumor models. For example, flavopiridol treatment leads to transcriptional repression of MCL-1 via upregulation of E2F1 (25) . Whilst flavopiridol showed efficacy against melanoma in vitro (26), it was ineffective for metastatic melanoma patients as a single agent (27) . Melphalan is an alkylating agent used for isolated limb-perfusion treatment of metastatic melanoma and may be preferable to dacarbazine/temozolomide for melanomas with high O6-alkylguaninetransferase activity (28) . Melphalan has been observed to decrease MCL-1 levels in myeloma cells, sometimes resulting in cleavage of the protein (29) .
In the present study we investigated the extent to which MCL-1 and BFL-1, and their antagonist NOXA, affect sensitivity of melanoma cells to ABT-737, and thus whether combination therapy targeting MCL-1 and BFL-1 in addition to BCL-2, BCL-XL and BCL-w has promise in the context of melanoma. The activity of MCL-1 and BFL-1 was manipulated by overexpression of NOXA, by shRNA-mediated knockdown of MCL-1 or by cytotoxic drugs. The contribution of BFL-1 to sensitivity to ABT-737 was examined by ectopic expression of NOXA variants with altered MCL-1 and BFL-1 affinities. The consequences for sensitivity to ABT-737 were assayed in 2D and 3D models in vitro and contrasted with observations in a tumor xenograft model. 
Material and Methods

Cells and Cell culture
The human melanoma cell lines IgR3, SKMel28, MelCV, MM200, MelRM and Me4405 were grown as described (30) and authenticated using AmpFISTR profiling as described (31) . C8161, 1205Lu and WM793 (32) were grown as described (33) ; the latter were authenticated by STR fingerprinting (Genomics Facility, The Wistar Institute, Philadelphia, PA). MelRM/NOXA and MM200/NOXA clones matched the parent lines in microsatellite analyses of 12 loci performed by the Australian Genome Research Facility Ltd (Parkville, Victoria, Australia), which also confirmed the purity.
Unnecessary passaging was avoided; experiments with manipulated cell lines were performed within 2 passages of reference stocks.
Immunoblot analysis
Cells were lysed in 10 mM Tris-HCl, pH 8, 5 mM EDTA, 0.1% Triton X-100 and protease inhibitor cocktail (Sigma P8340, per directions), 100 μL per 10 6 cells. Tumors were homogenized and sonicated in 10 mM Tris, pH 7.4, 10 mM KCl, 1. 
NOXA overexpression
HA-tagged human NOXA cDNA was inserted into retroviral vector pQC-X-IRES-CD4, a derivative of pQCXIX (Clontech) containing a human CD4 marker. The mNoxaB variants in pMIG retroviral vector carrying an EGFP marker have been described (14) .
Constructs were packaged with Phoenix amphotropic cells (34) and used to transduce melanoma cells. Transduced cells were sorted by flow cytometry, expanded and frozen as reference stocks. These remained >99% positive on retest. Single cell clones were derived from pools by serial dilution, facilitated with 40% v/v conditioned medium from the parent cell line.
2D drug sensitivity assays
Proliferation inhibition assays were performed as described (35, 36) , on 4 occasions.
Sensitization to ABT-737 by melphalan or flavopiridol, and vice versa, was assessed by
Research. proliferation inhibition assays testing all combinations of a range of ABT-737 with flavopiridol or melphalan concentrations, as shown, applied simultaneously.
Melanoma 3D-spheroid assays
Melanoma spheroids were prepared as described (37, 38) . After embedding into a gel of bovine collagen I, spheroids were treated with ABT-737 and/or flavopiridol at the concentrations and times indicated. Termination of the experiments: Spheroids were washed thrice in PBS before live-dead staining with 4 mM calcein-AM and 2 mM ethidium bromide (Invitrogen) for 1 h at 37 o C. Images were taken using a Nikon-300 inverted fluorescence microscope. For re-culture spheroids were plucked from the matrix with a pipette and plated in complete medium for expansion by 2D adherent growth.
Spheroid sizes were quantified by image analysis using ImageJ software (NIH).
Xenograft studies
The flanks of 6-week old CB17 NOD/SCID male mice were injected subcutaneously 
Statistical analysis
Comparisons of IC50s of manipulated cell lines with parent or control lines were t-tests.
As drug resistance raw data are by nature positively skewed, tests were performed on logtransformed data. Differences between xenograft or spheroid growth rates were detected as interactions between time and treatment factors in 2-way mixed ANOVA with time as a repeated measure.
Results
MCL-1 inhibition is sufficient for sensitization of melanoma cells to ABT-737
The sensitivity of melanoma cell lines to ABT-737, versus other tumor lines, was tested by proliferation inhibition assay. Of the 9 melanoma lines examined, 8 were insensitive to ABT-737 compared to, e.g. lymphoid cell lines (Table 1) . However, overexpression of NOXA in 6 melanoma lines by retroviral transduction (Fig. 1A) (Fig. 1A) . The strong sensitization was observed in both transduced cell pools and in single-cell clones derived from them (Table 1) and cannot be attributed to effects of NOXA overexpression on growth rates (Supplementary Table S1 ). NOXA overexpression had no consistent effect on levels of other proapoptotic (e.g. PUMA) or antiapoptotic proteins, although lines with more MCL-1 tolerated more NOXA overexpression ( Fig. 1A; supplementary Fig. S2 ). In contrast to overexpression, NOXA knockdown modestly decreased sensitivity to ABT-737 (Table 1) .
NOXA directly antagonizes MCL-1 and BFL-1; knockdown of MCL-1 in two melanoma cell lines (Fig. 1C ) also sensitized to ABT-737 (up to 9-fold), although not as much as NOXA overexpression (Table 1 ). Incomplete MCL-1 knockdown is likely part of the reason. Secondly, MCL-1 knockdown was accompanied by reduction of NOXA levels ( (Table 1) , MelRM or C8161 cell (not shown).
The relative importance of functional MCL-1 and BFL-1 inhibition is difficult to evaluate with incomplete knockdowns and so was assessed using Noxa-Bim chimeras containing Noxa BH3 domains in an inert Bim backbone; mNoxaB binds and inhibits MCL-1 only, whereas mNoxaB E74F inhibits both MCL-1 and BFL-1 (14) . Overexpression of either variant ( Fig. 1E ) resulted in dramatic sensitization to ABT-737 (Table 1) had most effect, inhibition of MCL-1 alone appears to be sufficient for the dramatic sensitization to ABT-737 in this context.
NOXA overexpression sensitizes 3D melanoma spheroids to ABT-737
Our 3D spheroid model mimics tumor architecture and microenvironment (37, 38) and is used for investigating drug effects on growth, invasion and viability of melanoma cells, which mimic those of treatment in vivo (2, 39, 40) .
Spheroids derived from sorted pools of MM200/NOXA cells were strongly sensitized to ABT-737 in 3-day assays, reflected in dose-dependent inhibition of proliferation and invasion as well as decreased viable cell staining (calcein-AM) and increased dead cell staining (ethidium bromide) compared to control spheroids (Fig. 1G) . NOXA overexpression also did not affect growth or invasion of the matrix ( Supplementary Fig.   S3 ).
Sensitization to ABT-737 by drugs that alter NOXA and/or MCL-1 levels
Since increased NOXA expression strongly sensitized melanoma cells to ABT-737, its combination with cytotoxic drugs that induce NOXA or repress MCL-1 may be an attractive therapeutic strategy. Drugs that have been reported to alter MCL-1 levels, melphalan (29) and flavopiridol (25) , were therefore tested as sensitizers to ABT-737.
In our hands, melphalan yielded only modest and transient increases in NOXA levels in MM200 and Me4405 cells, which disappeared within 24 h (Fig. 2A) . Flavopiridol had greater and more lasting effects in both cell lines tested but they were strongly dosedependent -lower doses raised NOXA levels whereas higher doses had the opposite effect ( Fig. 2A) . Thus, the net effects were time-and dose-dependent. Moreover, the changes in NOXA levels appeared to be mirrored by similar changes in MCL-1 levels, which would tend to counteract each other.
Nevertheless, flavopiridol sensitized both MM200 and Me4405 cells to ABT-737 by more than 12 and 8 fold respectively (Table 2, The same dataset showed the effects of ABT-737 on sensitivity of the cells to the cytotoxic drugs ( Table 2, supplementary Fig. S4B, D) . Even at very high concentrations of ABT-737, there was little sensitization to either flavopiridol or melphalan. There can be little doubt that ABT-737 was inhibiting BCL-2, BCL-XL and BCL-w, as the Ki for these proteins was reported as <1 nM (13) and we observed that low concentrations of ABT-737 in complete medium were sufficient to kill melanoma cell lines that overexpressed NOXA (Fig. 1B & Table 1 ). Thus, reported cooperativity between ABT-737 and cytotoxic drugs can be due to sensitization to ABT-737 rather than the converse.
3D melanoma spheroids were also sensitized to ABT-737 by flavopiridol. Growth of the spheroids (increase in radius, Fig. 2B ) was expressed relative to the controls (0 ȝM ABT-737), analogous to cytotoxicity curves for flat cultures (Fig. 2C) . In the presence of 80- 160 nM flavopiridol there was obvious sensitization to ABT-737. This also manifested as reduced cell viability (Fig. 2F) . At 320 nM flavopiridol, there was no additional effect from ABT-737 on spheroid growth but still an enhancement of cell killing (Fig. 2F) . The converse sensitization to flavopiridol by ABT-737 was notably weaker, as observed in 2D culture ( Fig. 2D, E ; compare 2D culture results in supplementary Fig. S4 and Table   2 ). A concentration of 1 μM ABT-737 was sufficient for this modest sensitization, consistent with on-target effect.
Effects of manipulating MCL-1 and NOXA on sensitivity of melanoma xenografts to ABT-
737
NOXA overexpression or MCL-1 knockdown markedly sensitized melanoma cells to ABT-737 in vitro, so it was of interest to ascertain whether the same occurs in vivo.
MM200 cells in which MCL-1 was knocked down, or which overexpressed NOXA, were engrafted into CB17 NOD/SCID mice and treated with ABT-737 daily for 21 days.
Surprisingly, ABT-737 had little effect on xenograft growth under this regimen, compared to vehicle-treated mice (Supplementary Fig. S5 ). Initial experiments with MM200/NOXA cells were performed with transduced cell pools purified by flow cytometry (Supplementary Fig. S5A ). It was anticipated that xenografts of a single-cell clone would exhibit greater sensitivity to ABT-737 simply because it harbored less heterogeneity than the pool but, again, there was no difference in rate of growth of the ABT-737-and vehicle-treated tumors (Fig. 3A) .
Blood samples from treated mice showed thrombocytopenia (0.62 ± 0.07 x10 6 /μL vs. p<0.001), (Fig. 3B, C) , confirming uptake of ABT-737 into the circulation with cellular consequences similar in magnitude to those obtained by others using the same treatment regimen (41) . The xenografts were always vascularized.
There was no evidence that insensitivity to ABT-737 in vivo reflected selection during engraftment for cells expressing less NOXA, since the levels in the tumors at time of sacrifice were not different from that of the injected cells, whether the tumors were derived from a single cell clone (Fig. 3D) or even transduced pools (Supplementary Fig.   S6 ). Explants grown from tumors retained sensitivity to ABT-737 in 2D cytotoxicity assays (Fig. 3E) . Thus, neither the engraftment itself nor treatment with ABT-737 selected for stable resistance to ABT-737, suggesting that insufficient amounts reached the tumors in vivo.
Effects of delayed ABT-737 treatment on melanoma spheroid growth
The 3D spheroid model provides insight into the difference in response of NOXA overexpressing melanoma cells to ABT-737 in vitro and in vivo. As noted above, spheroids derived from NOXA-transduced MM200 cell pools that were treated with ABT-737 showed a strong initial response (Fig. 1G) . Similar results were obtained with spheroids derived from homogeneous single cell clones of MM200/NOXA (Fig. 4) and C8161/NOXA cells ( Supplementary Fig. S7 
cytotoxicity assays cells from ABT-737-treated spheroids were resistant to ABT-737, whereas cells from untreated spheroids remained sensitive (Fig. 4D) . Moreover, immunoblotting showed that the resistant cells had lost overexpression of NOXA (Fig.   4E ).
To model the growth of the xenografts, spheroids were then allowed 7 days unfettered growth before treatment with ABT-737. It is striking that there was far less impact on proliferation or invasion of these larger spheroids, but a noticeable effect on viability in the periphery of the spheroids (Fig. 4C, supplementary Fig. S7D ), suggesting that diffusion of ABT-737 into larger melanoma masses may be limiting. A number of other cancer types are sensitive to ABT-737 and there is evidence that its addition to chemotherapy regimens is beneficial (15) , particularly in combination with antineoplastic drugs that alter the activity of MCL-1 and NOXA (46, 47) . Two examples are melphalan and flavopiridol, which are both reported to repress MCL-1, e.g. in lung carcinoma and myeloma cells (25, 29) . In our hands, flavopiridol was more efficient at altering NOXA and MCL-1 levels in melanoma lines. It was striking that, in each cell line tested, doses around the IC50 induced both proteins whereas higher concentrations repressed both. Such coordinated changes in NOXA and MCL-1 levels, not reported previously, would tend to counteract. Even so, at concentrations around its IC50, 
thrombocytopenia is not consistent with that explanation. The subcutaneous melanoma xenografts were observed to be vascularized and s.c. SCLC xenografts in other studies responded to ABT-737 (16) but it is nevertheless possible that melanomas in other locations, such as metastases to the lymph nodes, lungs or liver, are more accessible to the compound, as it has been effective against model tumors in such locations, either as a single agent or a potentiator for other drugs (13, (15) (16) (17) (18) 54) .
A third, related, possibility is inadequate diffusion of ABT-737 into the melanoma xenografts (55), which could also be specific to the cell type. 3D-spheroids grown in vitro from melanoma cells overexpressing NOXA were less sensitized to ABT-737 than flat cultures, and resistance developed early with loss of NOXA expression. Moreover, ABT-737 was less effective when the spheroids were allowed to grow for 7 days prior to exposure, by which time they numbered >10 5 cells. Xenografts consisted of an injected bolus of 10 6 cells and were allowed 7 days growth before treatment with ABT-737 so the lack of response in vivo may reflect the insensitivity of large spheroids in vitro. If so, it does not represent an obstacle in principle. The MM200 cells tested may not be representative melanoma xenografts, as suggested by the responsiveness of A375 xenografts to ABT-737 plus temozolomide (52) . In any case, development of more diffusible BH3 mimetics (56) , which have improved oral bioavailability, charge balance and metabolism properties, will likely obviate such problems.
In conclusion, our results indicate that addition of BH3-mimetics to current drug regimens or development of new drug combinations with BH3-mimetics are avenues worth exploring for melanoma therapy, particularly if dosing schedules can be developed to maintain the most favorable balance between MCL-1 and NOXA activity over time.
Research. Values were derived from at least four experiments. ALL = Acute Lymphoblastic Leukaemia. CML = Chronic Myeloid Leukemia.
Sensitization was computed relative to the parent cell line or vector-transduced controls, as shown.
Statistically significant differences with the IC 50 of the parent or control-transduced line are shown as * p<0.01, ** p<<0.0001, or ns where not significant, determined by Student's T-test of log-transformed data. Where the parent IC50 was not calculable, the lower bound was used. 1 NOXA and BFL1 knockdowns were performed in tandem with shared controls. The MCL1 knockdowns were a separate experiment. In each case, 2 of a total of 5 knockdown pools are shown.
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